Injectable Hydrogel Depots for Self-replicating mRNA Vaccine Delivery
Full Description
While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy
humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of
catheters and prosthetic devices. With currently approved therapy, about one-third of patients diagnosed with
SA bacteremia succumb, accounting for more annual deaths than HIV, tuberculosis, and viral hepatitis
combined. This R01 will develop an injectable vaccine depot comprising: (a) previously published cationic
polymers to condense and charge neutralize anionic self-replicating mRNA (SR-mRNA) vaccines into
nanometer-sized particles (i.e., “polyplexes”) that are then incorporated within (b) our recently reported
injectable biodegradable gel of N-succinyl-chitosan (S-CS) and oxidized alginate (O-Alg). Ultimately, the
temporary CS-Alg depots completely biodegrade into non-toxic by-products that are eliminated. This project
will generate a self-immunizing biomaterials technology that is applied ONCE that is superior in immunization
versus repeated systemic bolus injections.
Grant Number: 5R01AI162840-04
NIH Institute/Center: NIH
Principal Investigator: James Bryers
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click